GSK Investigator-sponsored studies programme


Belimumab 2019 ISS proposals


Currently accepting belimumab ISS proposals up to January 15th, 2019, with next review committee meeting in Q1-2019


Belimumab ISS Proposals can be submitted any time during the year up to January 15th, 2019, however GSK belimumab ISS committee will review them once a year (not applicable for other GSK ISS).  The next cycle of review by the belimumab ISS committee will begin in Q1-2019. Review decisions will be communicated by Q2-2019 .

GSK belimumab ISS committee is committed to the above review timelines, however, the review process might take longer for certain proposals.

The following areas are of interest to the Belimumab ISS Committee:
- Use of belimumab in SLE in clinical practice
- Association of biomarkers with clinical outcomes in SLE
- Contribution to scientific knowledge of SLE disease state
- BLyS inhibition with focus on other systemic and non-systemic autoimmune diseases and consistent with the belimumab mechanism of action (MOA)
- Contribution to scientific knowledge of belimumab
- Critical unmet medical needs based on belimumab MOA.

Details and timelines described above are not applicable and cannot be used as reference for other GSK ISS areas of interest.

If you have any questions, please contact your local GSK Medical contact (e.g. MSL, others)

Click on "Submit Application" below to begin the process.

Powered by ideaPoint, Inc.

Posted: 01-22-2018
Created: 01-22-2018
Modified: 02-07-2018

Terms of use Accessibility Cookie policy Privacy
© 2001-2018 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.